About: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 February 2001

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в лютому 2001 (uk) article scientifique publié en 2001 (fr) im Februar 2001 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en febreru de 2001 (ast) artikull shkencor i botuar më 01 shkurt 2001 (sq) scientific article published on 01 February 2001 (en)
publication date	wds:Q73395687-1BF398EF-E92E-4A97-A1C9-F2A6AEA2EDC6
publication date	2001-02-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73395687-BFD536DA-A171-48AB-8380-ED87B278B166
language of work or name	English
author name string	wds:Q73395687-0641862A-66F9-4E1D-8476-BC3C50FB44B5 wds:Q73395687-1CD69187-A6CC-4700-AC2C-A9BD0DDC2611 wds:Q73395687-395783F2-E2BB-4593-A7CD-C8560EE42697 wds:Q73395687-4D7C5BBC-DB70-40C8-A8B3-1BFE8B46E049 wds:Q73395687-A0757A1A-A72A-4810-B1EB-B13CA658775E wds:Q73395687-CD2E83EF-A421-4C73-99A6-CCD81B2BDBEF wds:Q73395687-DA4D1ED4-4BFE-459E-B1B2-2BDCEC9D395B wds:Q73395687-E154B09D-C9CD-4B10-8F1C-E47E79F48062 wds:Q73395687-E7E9BDD8-DA02-4506-9532-D1FFE640434E
author name string	S Shak M S Gordon M Talpaz G W Sledge K Margolin D Adelman R Benjamin E Holmgren S Stalter
rdfs:label	Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (en) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (nl) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (sq)
skos:prefLabel	Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (en) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (nl) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (sq)
name	Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (en) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (nl) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (sq)
title	wds:Q73395687-285838DE-748D-4B17-9589-1749CBD2DC87
title	Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer (en)
page(s)	wds:Q73395687-6718DCFB-343F-4333-BF41-05D64C902F75
page(s)	843-850
instance of	wds:Q73395687-09EB023A-AEF6-43C2-8652-7DDEA0932CD2
instance of	scholarly article
PubMed ID	wds:Q73395687-5451061C-ECA2-4C73-8064-5710F14F8A60
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11157038
PubMed ID	11157038
published in	wds:Q73395687-79743DD2-E6EB-427B-9DFA-5C5AB6FE273D
published in	Journal of Clinical Oncology
issue	wds:Q73395687-2FE10EA3-555E-47B5-95F4-1360FDA7E22F
volume	wds:Q73395687-8ECFCC7E-44CC-4C94-A057-662D73A4BDA5
issue	3
volume	19
DOI	wds:Q73395687-B4A31E26-B8A7-48D6-9CCA-788D682C1AE7
DOI	http://dx.doi.org/10.1200/JCO.2001.19.3.843
DOI	10.1200/JCO.2001.19.3.843
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73395687
is cites work of	Therapeutic antibodies against cancer Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC) Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs Angiogenesis modulation in cancer research: novel clinical approaches Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer Antiangiogenic therapies in early-stage breast cancer Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? Development of antibodies and chimeric molecules for cancer immunotherapy Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy Targeted agents for the treatment of advanced renal cell carcinoma Monoclonal antibody therapy of cancer Bevacizumab in the treatment of non-small-cell lung cancer Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications Targeting angiogenesis in cancer: clinical development of bevacizumab Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma Surgical therapy for colorectal metastases to the liver Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma Drug insight: VEGF as a therapeutic target for breast cancer Bevacizumab for the treatment of glioblastoma. Role of targeted agents in metastatic colorectal cancer. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model Dose escalation methods in phase I cancer clinical trials Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Bevacizumab: a review of its use in metastatic colorectal cancer Optimal management of brain metastases from breast cancer. Issues and considerations Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. Computational modeling of tumor response to vascular-targeting therapies--part I: validation CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software